Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors

被引：0

作者：

Denker, S. ^{[1
,2
]}

Bittner, A. ^{[1
,2
]}

Frick, M. ^{[1
]}

Kase, J. ^{[1
]}

Hoffmann, J. ^{[3
]}

Trenker, C. ^{[3
]}

Keller, U. ^{[2
,4
,5
,6
,7
]}

Bogner, C. ^{[8
]}

Huttmann, A. ^{[9
]}

Duhrig, J. ^{[9
]}

Janz, M. ^{[4
,7
]}

Mathas, S. ^{[4
,7
]}

Marks, R. ^{[10
,11
]}

Krohn, U. ^{[10
,11
]}

Bhattacharya, A. ^{[4
]}

Na, I. -K ^{[1
,2
]}

Gebauer, B. ^{[4
]}

Savic, L. J. ^{[4
]}

Hubner, N. ^{[7
]}

Akalin, A. ^{[12
]}

Eils, R. ^{[2
]}

Bullinger, L. ^{[1
,2
,5
,6
]}

Schmitt, C. A. ^{[1
,7
,13
]}

机构：

[1] Charite Univ Med Berlin, Med Klin mS Hamatol Onkol & Tumorimmunol, Campus Virchow Klinikum, Berlin, Germany

[2] Berlin Inst Hlth BIH, Berlin, Germany

[3] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol, Oncol,Immunol, Marburg, Germany

[4] Charite Univ Med Berlin, Berlin, Germany

[5] German Canc Res Ctr, Heidelberg, Germany

[6] German Canc Consortium DKTK, Heidelberg, Germany

[7] Max Delbruck Ctr Mol Med, Berlin, Germany

[8] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany

[9] Univ Duisburg Essen, Univ Klinikum Essen, Klin Hamatol, Essen, Germany

[10] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Fac Med, Freiburg, Germany

[11] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Med Ctr, Freiburg, Germany

[12] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Bioinformat & Omics Data Sci Platform, Berlin, Germany

[13] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V104

引用

页码：24 / 24

页数：1

共 50 条

[1] R-CHOP Plus Bortezomib Unpromising in Patients With DLBCL, While an Early Trial of R-CHOP Plus Everolimus Shows Remarkable Results
不详
AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 9 - 11
[2] Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
Geng, Hongzhi
Jia, Sixun
Zhang, Ying
Li, Jiaqi
Yang, Qin
Zeng, Liangyu
Zong, Xiangping
Lu, Yutong
Lu, Shuangzhu
Zhou, Jin
Li, Caixia
Wu, Depei
FRONTIERS IN IMMUNOLOGY, 2023, 14
[3] A non-randomized risk-adjusted comparison of lenalidomide plus R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
de Jonge, A. Vera
van Werkhoven, Erik
Dinmohamed, Avinash G.
Nijland, Marcel
Zwinderman, Aeilko H.
Bossuyt, Patrick M.
Veldhuis, Martine S.
Rutten, Emma G. G. M.
Mous, Rogier
Vermaat, Joost S. P.
Sandberg, Yorick
de Jongh, Eva
Bilgin, Yavuz M.
Boersma, Rinske
Koene, Harry
Kersten, Marie Jose
de Jong, Daphne
Chamuleau, Martine E. D.
BLOOD CANCER JOURNAL, 2023, 13 (01)
[4] A Propensity Score-Adjusted Comparison of Lenalidomide plus R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients
de Jonge, A. Vera
van Werkhoven, Erik D.
Dinmohamed, Avinash G.
Nijland, Marcel
Zwinderman, Aeilko H.
Bossuyt, Patrick M.
Veldhuis, Martine S.
Rutten, Emma G. G. M.
Mous, Rogier
Vermaat, Joost S. P.
Sandberg, Yorick
de Jongh, Eva
Bilgin, Yavuz M.
Boersma, Rinske
Koene, Harry R.
Kersten, Marie Jose
de Jong, Daphne
Chamuleau, Martine E. D.
BLOOD, 2022, 140 : 2059 - 2060
[5] Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
Johnson, Peter W. M.
Balasubramanian, Sriram
Hodkinson, Brendan
Shreeve, S. Martin
Sun, Steven
Srinivasan, Srimathi
Steele, Andrew J.
Vermeulen, Jessica
Sehn, Laurie H.
Wilson, Wyndham H.
BLOOD ADVANCES, 2023, 7 (10) : 2008 - 2017
[6] Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals
Denker, Sophy
Bittner, Aitomi
Frick, Mareike
Kase, Julia
Hoffmann, Joerg
Trenker, Corinna
Keller, Ulrich
Bogner, Christian
Huettmann, Andreas
Duerig, Jan
Janz, Martin
Mathas, Stephan
Marks, Reinhard
Krohn, Ulrike
Na, Il-Kang
Bullinger, Lars
Schmitt, Clemens A.
LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 84 - 92
[7] CHOP-R plus bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL)
Leonard, J. P.
Furman, R. R.
Cheung, Y. K.
Vose, J. M.
Glynn, P. W.
Ruan, J.
Martin, P.
Niesvizky, R.
LaCasce, A.
Chadburn, A.
Coleman, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[8] Phase III Trial of Subcutaneous Epcoritamab plus R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2
Sehn, Laurie
Chamuleau, Martine
Lenz, Georg
Clausen, Michael
Haioun, Corinne
Izutsu, Koji
Davies, Andrew
Zhu, Jun
Oki, Toshiko
Szafer-Glusman, Edith
Conlon, Rebekah
Chiou, Hueiyu
Ipe, David
Elliott, Brian
Wu, Jun
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S440 - S440
[9] Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies
Ayed, Ayed O.
Chiappella, Annalisa
Nowakowski, Grzegorz S.
Cavallo, Federica
Congiu, Angela Giovanna
Gaidano, Gianluca
Pederson, Levi
Laplant, Betsy R.
Macon, William R.
Musuraca, Gerardo
Re, Alessandro
Spina, Michele
Witzig, Thomas E.
Vitolo, Umberto
BLOOD, 2016, 128 (22)
[10] Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
Sehn, Laurie Helen
Chamuleau, Martine
Lenz, Georg
Clausen, Michael
Haioun, Corinne
Izutsu, Koji
Davies, Andrew John John
Zhu, Jun
Oki, Toshiko
Szafer-Glusman, Edith
Conlon, Rebekah
Chiou, Hueiyu
Ipe, David
Elliott, Brian
Wu, Jun
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →